Table 3.
Characteristics of reports to the VAERS following mRNA COVID-19 vaccination. .
| Characteristics | Primary series | Booster dose | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose 1 | Dose 2 | In total | Dose 3 | |||||||
| Cases | Noncases | Cases | Noncases | Cases | Noncases | Cases | Noncases | |||
| n(%) | 738 | 328,881 | 1,850 | 230,781 | 2,588 | 559,662 | 269 | 59,928 | 0.64 | |
| Sex | ||||||||||
| Female | 300 (40.65) | 229,761 (69.86) | 505 (27.30) | 156,113 (67.65) | 805 (31.11) | 385,874 (68.95) | 110 (40.89) | 37,549 (62.66) | < 0.05 | |
| Male | 427 (57.86) | 88,089 (26.78) | 1,329 (71.84) | 70,556 (30.57) | 1,756 (67.85) | 158,645 (28.35) | 156 (57.99) | 19,966 (33.32) | < 0.05 | |
| Not specified | 11 (1.49) | 11,031 (3.35) | 16 (0.86) | 4,112 (1.78) | 27 (1.04) | 15,143 (2.71) | 3 (1.12) | 2,413 (4.03) | ||
| Age (y) | ||||||||||
| <18 | 81 (10.98) | 20,591 (6.26) | 387 (20.92) | 10,606 (4.60) | 468 (18.08) | 31,197 (5.57) | 18 (6.69) | 2,275 (3.80) | < 0.05 | |
| 18-24 | 114 (15.45) | 16,765 (5.10) | 392 (21.19) | 11,054 (4.79) | 506 (19.55) | 27,819 (4.97) | 44 (16.36) | 2,532 (4.23) | 0.77 | |
| 25-44 | 256c(34.69) | 90,286 (27.45) | 528 (28.54) | 66,353 (28.75) | 784 (30.29) | 156,639 (27.99) | 95 (35.32) | 14,957 (24.96) | 0.03 | |
| 45-64 | 169 (22.90) | 95,876 (29.15) | 305 (16.49) | 73,453 (31.83) | 474 (18.32) | 169,329 (30.26) | 58 (21.56) | 18595 (31.03) | 0.44 | |
| ≥65 | 74 (10.03) | 68,805 (20.92) | 152 (8.22) | 56,458 (24.46) | 226 (8.73) | 125,263 (22.38) | 52 (19.33) | 18,588 (31.02) | < 0.05 | |
| Not specified | 44 (5.96) | 36,558 (11.12) | 86 (4.65) | 12,857 (5.57) | 130 (5.02) | 49,415 (8.83) | 2 (0.74) | 2,981 (4.97) | < 0.05 | |
| Seriousness | ||||||||||
| Death | 13 (1.76) | 2,994 (0.91) | 17 (0.92) | 4,924 (2.13) | 30 (1.16) | 7,918 (1.41) | 1 (0.37) | 719 (1.20) | 0.30 | |
| Life-threatening | 90 (12.20) | 3,356 (1.02) | 277 (14.97) | 4,549 (1.97) | 367 (14.18) | 7,905 (1.41) | 36 (13.38) | 789 (1.32) | 0.92 | |
| Hospitalization | 355 (48.10) | 12,328 (3.75) | 1,175 (63.51) | 25,706 (11.14) | 1,530 (59.12) | 38,034 (6.80) | 131 (48.70) | 4,445 (7.42) | < 0.05 | |
| Disability | 36 (4.88) | 3,682 (1.12) | 90 (4.86) | 5,615 (2.43) | 126 (4.87) | 9,297 (1.66) | 9 (3.35) | 822 (1.37) | 0.54 | |
| ER visit | 355 (48.10) | 37,648 (11.45) | 953 (51.51) | 31,717 (13.74) | 1,308 (50.54) | 69,365 (12.39) | 149 (55.39) | 6,365 (10.62) | < 0.05 | |
| Symptoms | ||||||||||
| Myocarditis | 370 (50.14) | / | 1,066 (57.62) | / | 1,436 (55.49) | / | 136 (50.56) | / | 0.12 | |
| Pericarditis | 309 (41.87) | / | 620 (33.51) | / | 929 (35.90) | / | 117 (43.49) | / | < 0.05 | |
| Myopericarditis | 59 (7.99) | / | 164 (8.86) | / | 223 (8.62) | / | 16 (5.95) | / | 0.08 | |
| Manufacturer | ||||||||||
| Pfizer-BioNTech | 407 (55.15) | 147,442 (44.83) | 1,275 (68.92) | 131,427 (56.95) | 1,682 (64.99) | 278,869 (49.83) | 159 (59.11) | 30,941 (51.63) | 0.05 | |
| Moderna | 331 (44.85) | 181,439 (55.17) | 575 (31.08) | 99,354 (43.05) | 906 (35.01) | 280,793 (50.17) | 110 (40.89) | 28,987 (48.37) | 0.11 | |
VAERS, Vaccine Adverse Event Reporting System; mRNA, messenger RNA; COVID-19, coronavirus disease 2019.